measure the outcome of mental health care with the help of advanced EEG analytics and Machine Learning predictive biomarker technologies. We provide the platform as a service for mental health care providers servicing those who are afflicted with addiction, depression, PTSD, anxiety, and ASD. Divergence also works with pharmaceutic technology companies to help validate the effectiveness of their compounds and treatments with neuroscience, ML and AI. In particular, we help companies that work with novel psychedelic therapy to validate the effects of their drugs and therapies by building biomarker model with EEG data in our research platform.